Latest Insider Transactions at Pieris Pharmaceuticals, Inc. (PIRS)
This section provides a real-time view of insider transactions for Pieris Pharmaceuticals, Inc. (PIRS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PIERIS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PIERIS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2024
|
George M Jenkins Director |
BUY
Open market or private purchase
|
Direct |
4,000
+2.17%
|
$48,000
$12.93 P/Share
|
|
Dec 13
2024
|
Bvf Partners L P |
BUY
Other acquisition or disposition
|
Direct |
438,929
+40.04%
|
-
|
|
Dec 12
2024
|
James A Geraghty Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1
-100.0%
|
$0
$0.01 P/Share
|
|
Aug 12
2024
|
Adar1 Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,000
+3.24%
|
$45,000
$15.88 P/Share
|
|
Aug 09
2024
|
Adar1 Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,000
+2.3%
|
$42,000
$14.89 P/Share
|
|
Aug 07
2024
|
James A Geraghty Director |
BUY
Open market or private purchase
|
Direct |
1
+50.0%
|
$1
$1.0 P/Share
|
|
May 25
2023
|
Christopher P Kiritsy Director |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$0
$0.85 P/Share
|
|
May 13
2022
|
Tim Demuth Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+50.0%
|
$6,000
$1.71 P/Share
|
|
Aug 30
2021
|
Shane Olwill Chief Development Officer |
SELL
Open market or private sale
|
Direct |
38,400
-53.84%
|
$192,000
$5.08 P/Share
|
|
Aug 30
2021
|
Shane Olwill Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,400
+47.15%
|
$38,400
$1.52 P/Share
|
|
Jul 21
2020
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,900,000
-34.08%
|
$3,800,000
$2.95 P/Share
|
|
Sep 06
2019
|
Bvf Partners L P |
SELL
Open market or private sale
|
Direct |
50,000
-0.82%
|
$200,000
$4.5 P/Share
|
|
Jan 30
2019
|
Bvf Partners L P |
SELL
Other acquisition or disposition
|
Direct |
5,000,000
-70.91%
|
-
|
|
Apr 30
2018
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,000,000
-19.55%
|
$6,000,000
$6.35 P/Share
|
|
Feb 13
2018
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,897
-0.15%
|
$63,176
$8.98 P/Share
|
|
Feb 13
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
7,897
+0.07%
|
$31,588
$4.88 P/Share
|
|
Jan 03
2018
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,709,620
-24.1%
|
$11,967,340
$7.35 P/Share
|
|
Dec 18
2017
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
147,635
-2.04%
|
$738,175
$5.7 P/Share
|
|
Dec 18
2017
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
147,635
+0.16%
|
$295,270
$2.32 P/Share
|